Intelligencia
Intelligencia offers AI-powered solutions to de-risk drug development and enhance decision-making, providing SaaS products like Portfolio Optimizer and Clinical Development Insights. Founded in 2017 and headquartered in New York, the company specializes in data and insights for clinical development, employing 110 individuals globally.
AI-Powered Solutions for Drug Development
Intelligencia offers advanced AI-powered solutions designed to de-risk the process of drug development and enhance decision-making capabilities. The company focuses on utilizing artificial intelligence to measure the likelihood of success for drugs across multiple therapeutic areas. This includes tools for probability of success (PoS) assessments, which help identify underlying drivers that contribute to technical and regulatory risk in drug development. Trusted by leading pharmaceutical organizations, Intelligencia aims to improve the predictability and efficiency of clinical development through comprehensive and transparent AI-driven analysis.
SaaS Products by Intelligencia
Intelligencia provides several SaaS products that are central to its offerings. The Intelligencia Portfolio Optimizer is a patented platform that delivers AI-powered insights to optimize pharmaceutical portfolios. Another key product, Clinical Development Insights, offers data visualizations into the competitive landscape, enabling better decision-making in clinical development. These SaaS products are built on a foundation of precise, high-quality data and deliver real-time tracking of clinical programs. Using proprietary ontologies, Intelligencia ensures the harmonization and consistency of data for an effective risk evaluation.
History of Intelligencia
Intelligencia was founded in 2017 with the mission to improve the global pharmaceutical industry through the application of advanced artificial intelligence. The company is headquartered in New York and has additional offices in San Francisco and Athens, Greece. With a team of 110 employees globally, Intelligencia has established itself as a reliable provider of AI-powered solutions that support the drug development lifecycle. Over the years, Intelligencia has achieved high prospective accuracy in real-world predictions and has been awarded a U.S. patent for its innovative methods in assessing drug success probabilities.
Intelligencia's Role in De-Risking Clinical Development
Intelligencia specializes in providing data and insights that are crucial for de-risking clinical development. By offering a single source of quality, harmonized data, the company ensures consistent evaluation of risks associated with clinical programs. Intelligencia's patented AI-powered assessments deliver state-of-the-art explainable AI, providing transparency into probability of technical and regulatory success (PTRS) predictions. Their proprietary tools help organizations significantly enhance decision-making power, particularly for phase transition assessments and PTRS calculations.
Global Presence and Team at Intelligencia
Headquartered in New York, Intelligencia has expanded its presence to key global locations with offices in San Francisco and Athens, Greece. The company employs 110 individuals worldwide, creating a diverse and skilled team committed to improving clinical development processes through AI and data-driven insights. The strategic positioning of its offices allows Intelligencia to collaborate closely with leading pharmaceutical organizations globally, ensuring that their clients benefit from cutting-edge technologies in drug development and risk management.